Lifeboat Foundation

Caltech scientists have introduced a revolutionary machine-learning-driven technique for accurately measuring the mass of individual particles using advanced nanoscale devices.

This method could dramatically enhance our understanding of proteomes by allowing for the mass measurement of proteins in their native forms, thus offering new insights into biological processes and disease mechanisms.

Caltech scientists have developed a machine-learning-powered method that enables precise measurement of individual particles and molecules using advanced nanoscale devices. This breakthrough could lead to the use of various devices for mass measurement, which is key to identifying proteins. It also holds the potential to map the complete proteome—the full set of proteins in an organism.

Scientists studying viruses at the University of Wisconsin-Madison recently opened their lab door for a tour, looking to shine a light on their work after being targeted by a Republican bill.

The legislation would have prohibited some of the research that has been done in the past in Madison…

The bill would have ended all so-called “gain-of-function” research at higher education institutions in the state, and cut funding from any university that continued such experiments.

Continue reading “Under scrutiny, UW-Madison virus lab opens its doors” »

A way to re grow new parts, perfect DNA match, eventually? Will take Agi / ASI to realize full potential, we ll see.

For this, the researchers have created a compact bioprinter to develop biological tissues with microfilament structures. He is now working to bring this technology to market.

Continue reading “3D laser bioprinter designed for precise human tissue engineering” »

Thanks to an algorithm created by an Idaho State University professor, the way engineers, doctors, and physicists tackle the hard questions in their respective fields could all change.

Emanuele Zappala, an assistant professor of mathematics at ISU, and his colleagues at Yale have developed the Attentional Neural Integral Equations algorithm, or ANIE for short. Their work was recently published in Nature Machine Intelligence and describes how ANIE can model large, complex systems using data alone.

“Natural phenomena–everything from plasma physics to how viruses spread–are all governed by equations which we do not fully understand,” explains Zappala. “One of the main complexities lies in long-distance relations between different data points in the systems over space and time. What ANIE does is it allows us to learn these complex systems using just those known data points.”

Life Biosciences is a company co-founded by the celebrity geroscientist David Sinclair and is based on his Harvard team’s research into partial cellular reprogramming. In the heated race to translate this promising technology to the clinic, Life has emerged as one of the favorites, inching closer towards clinical trials in humans. Life is counting on its proprietary reprogramming technology that uses only three out of four classic reprogramming factors and on its strong team of scientists and managers. We talked to Dr. Sharon Rosenzweig-Lipson, Life’s Chief Scientific Officer, about the company’s journey, delving deep into the technology and its future.

I’ll start by saying that Life Biosciences is one of the most exciting companies in the longevity field. You might actually become the first company to have a partial reprogramming-based therapy approved.

At Life Biosciences, we’re focused on something that matters to everyone: helping people stay healthier as they age. We’re working on what we call cellular rejuvenation technologies, basically finding ways to turn back the clock in cells and make them more youthful. I came on board as Chief Scientific Officer about a year and a half ago, but I actually got to know the company pretty well before that. I consulted for them for a year, which gave me a chance to look under the hood, see the science they were doing, and I got really excited about what I saw.

Accumulation of senescent cells drives aging and age-related diseases. Senolytics, which selectively kill senescent cells, offer a promising approach for treating many age-related diseases. Using a senescent cell-based phenotypic drug discovery approach that combines drug screening and drug design, we developed two novel flavonoid senolytics, SR29384 and SR31133, derived from the senolytic fisetin. These compounds demonstrated enhanced senolytic activities, effectively eliminating multiple senescent cell types, reducing tissue senescence in vivo, and extending healthspan in a mouse model of accelerated aging. Mechanistic studies utilizing RNA-Seq, machine learning, network pharmacology, and computational simulation suggest that these novel flavonoid senolytics target PARP1, BCL-xL, and CDK2 to induce selective senescent cell death. This phenotype-based discovery of novel flavonoid senolytics, coupled with mechanistic insights, represents a key advancement in developing next-generation senolyticss with potential clinical applications in treating aging and age-related diseases.

LJN and PDR are cofounders of Itasca Therapeutics, developing senotherapeutics for aging and age-related diseases. LJZ, LJN, PDR and the University of Minnesota have filed a provisional patent on the application of flavonoid analogs, including SR29384 and SR31133, as a strategy to treat age-related diseases.

Prof. Leslie Leiserowitz first became intrigued by malaria when he was a young boy in South Africa. His father, who scouted the continent in search of wood for the family business, brought back not only tales of elephants and gorillas but also skin rashes and ringing in his ears, side effects of the quinine he took to prevent malaria.

An estimated one in five Americans live with chronic pain and current treatment options leave much to be desired. Feixiong Cheng, Ph.D., Director of Cleveland Clinic’s Genome Center, and IBM are using artificial intelligence (AI) for drug discovery in advanced pain management. The team’s deep-learning framework identified multiple gut microbiome-derived metabolites and FDA-approved drugs that can be repurposed to select non-addictive, non-opioid options to treat chronic pain.

The findings, published in Cell Press, represent one of many ways the organizations’ Discovery Accelerator partnership is helping to advance research in healthcare and life sciences.

Treating chronic pain with opioids is still a challenge due to the risk of severe side effects and dependency, says co-first author Yunguang Qiu, Ph.D., a postdoctoral fellow in Dr. Cheng’s lab whose research program focuses on developing therapeutics for nervous system disorders. Recent evidence has shown that drugging a specific subset of pain receptors in a protein class called G protein-coupled receptors (GPCRs) can provide non-addictive, non-opioid pain relief. The question is how to target those receptors, Dr. Qiu explains.

CRISPR/Cas9 is a gene editing tool that has revolutionized biomedical research and led to the first FDA-approved CRISPR-based gene therapy. However, until now, the precise mechanism of exactly how this tool works and avoids creating detrimental off-target effects was not well understood.